Vertex Pharmaceutic (VRTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2017 | 03-2017 | 12-2016 | 09-2016 | 06-2016 | |
| Sales | 544,135 | 714,718 | 458,706 | 413,783 | 431,608 |
| Cost of Goods | 71,205 | 46,988 | 60,482 | 54,077 | 45,252 |
| Gross Profit | 472,930 | 667,730 | 398,224 | 359,706 | 386,356 |
| Operating Expenses | 420,428 | 397,876 | 359,066 | 378,510 | 383,255 |
| Operating Income | 52,707 | 270,842 | 39,640 | -18,727 | 3,353 |
| Interest Expense | 14,664 | 16,765 | 20,439 | 20,140 | 20,155 |
| Other Income | -2,537 | -544 | 1,105 | -167 | -1,219 |
| Pre-tax Income | 35,506 | 253,533 | 20,306 | -39,034 | -18,021 |
| Income Tax | 4,337 | 3,985 | -7,453 | 503 | 18,130 |
| Net Income Continuous | 31,169 | 249,548 | 27,759 | -39,537 | -36,151 |
| Minority Interests | 13,173 | 1,792 | -5,186 | -696 | 28,374 |
| Net Income | $17,996 | $247,756 | $32,945 | $-38,841 | $-64,525 |
| EPS Basic Total Ops | 0.07 | 1.01 | 0.13 | -0.16 | -0.26 |
| EPS Basic Continuous Ops | 0.13 | 1.01 | 0.11 | -0.16 | -0.15 |
| EPS Diluted Total Ops | 0.07 | 0.99 | 0.13 | -0.16 | -0.26 |
| EPS Diluted Continuous Ops | 0.12 | 1.00 | 0.11 | -0.16 | -0.15 |
| EBITDA(a) | $67,597 | $285,692 | $55,091 | $-4,158 | $18,316 |